Sabra Health Care REIT, Inc. (SBRA)
| Market Cap | 4.65B +8.2% |
| Revenue (ttm) | 815.66M +13.2% |
| Net Income | 156.19M +11.0% |
| EPS | 0.63 +5.3% |
| Shares Out | 252.19M |
| PE Ratio | 29.28 |
| Forward PE | 26.84 |
| Dividend | $1.20 (6.50%) |
| Ex-Dividend Date | May 15, 2026 |
| Volume | 3,760,134 |
| Open | 17.61 |
| Previous Close | 17.67 |
| Day's Range | 17.60 - 18.55 |
| 52-Week Range | 17.17 - 21.28 |
| Beta | 0.63 |
| Analysts | Buy |
| Price Target | 22.69 (+22.95%) |
| Earnings Date | Apr 29, 2026 |
About SBRA
Sabra Health Care REIT, Inc. operates as a self-administered, self-managed real estate investment trust that, through its subsidiaries, owns and invests in real estate serving the healthcare industry throughout the United States and Canada. Sabra Health Care REIT, Inc. is incorporated on May 10th, 2010 and is based in Tustin, United States.
Financial Performance
In 2025, Sabra Health Care REIT's revenue was $775.76 million, an increase of 10.41% compared to the previous year's $702.64 million. Earnings were $155.61 million, an increase of 22.81%.
Financial StatementsAnalyst Summary
According to 13 analysts, the average rating for SBRA stock is "Buy." The 12-month stock price target is $22.69, which is an increase of 22.95% from the latest price.
News
Sabra Health Care REIT, Inc., Issues Business Update and will Participate in Nareit's REITweek 2026 Investor Conference
TUSTIN, Calif.--(BUSINESS WIRE)---- $SBRA #NAREIT--In conjunction with upcoming investor meetings, Sabra Health Care REIT, Inc. (Nasdaq: SBRA) has issued a business update, which is available on the c...
Sabra Health Care price target raised to $25 from $23 at BofA
BofA analyst Farrell Granath raised the firm’s price target on Sabra Health Care (SBRA) to $25 from $23 and keeps a Buy rating on the shares. The firm updated its…
Sabra Health Care price target raised to $22 from $21 at Scotiabank
Scotiabank raised the firm’s price target on Sabra Health Care (SBRA) to $22 from $21 and keeps a Sector Perform rating on the shares. The firm is updating its price…
Sabra Health Care price target raised to $22 from $21 at UBS
UBS analyst Michael Goldsmith raised the firm’s price target on Sabra Health Care (SBRA) to $22 from $21 and keeps a Neutral rating on the shares.
Sabra Health Care price target raised to $22 from $21 at Cantor Fitzgerald
Cantor Fitzgerald analyst Richard Anderson raised the firm’s price target on Sabra Health Care (SBRA) to $22 from $21 and keeps a Neutral rating on the shares. Sabra’s long Senior…
Sabra Health Care REIT Earnings Call Transcript: Q1 2026
Strong Q1 results with robust investment activity, sequential and year-over-year growth in managed senior housing, and continued margin expansion. Guidance for 2026 was reaffirmed, with a focus on SHOP growth, AI initiatives, and a healthy balance sheet supporting future investments.
Sabra Health Care REIT Earnings release: Q1 2026
Sabra Health Care REIT released its Q1 2026 earnings on April 30, 2026, summarizing the period's financial results.
Sabra Health Care REIT Quarterly report: Q1 2026
Sabra Health Care REIT has published its Q1 2026 quarterly earnings report on April 30, 2026.
Sabra Health Care REIT Slides: Q1 2026
Sabra Health Care REIT has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on April 30, 2026.
Sabra Reports First Quarter 2026 Results; Reiterates 2026 Guidance
TUSTIN, Calif.--(BUSINESS WIRE)---- $SBRA #1Q26--Sabra Health Care REIT, Inc. (“Sabra,” the “Company” or “we”) (Nasdaq: SBRA) today announced its results of operations for the first quarter of 2026. F...
Sabra Health Care REIT Proxy statement: Proxy filing
Sabra Health Care REIT filed a proxy statement on April 24, 2026, providing details for shareholder voting and corporate governance matters.
Sabra Health Care REIT Proxy statement: Proxy filing
Sabra Health Care REIT filed a proxy statement on April 24, 2026, providing details for shareholder voting and corporate governance matters.
Sabra Health Care REIT, Inc. to Attend Wells Fargo's 29th Annual Real Estate Securities Conference
TUSTIN, Calif.--(BUSINESS WIRE)---- $SBRA #SBRA--Sabra Health Care REIT, Inc. (Nasdaq: SBRA) announced today that Rick Matros, the company's Chair and Chief Executive Officer, Michael Costa, the compa...
Sabra Health Care REIT, Inc. Announces First Quarter 2026 Earnings Release Date and Conference Call
TUSTIN, Calif.--(BUSINESS WIRE)---- $SBRA #1Q26--Sabra Health Care REIT, Inc. (Nasdaq: SBRA) announced today that it will issue its 2026 first quarter earnings release on April 29, 2026, after the clo...
REITs Have Been Rocked, These 4 Now Pay Up To 14.6%
Oil is up, and everything else is down. Stocks. Bonds.
Sabra Health Care price target raised to $22 from $21 at Wells Fargo
Wells Fargo analyst John Kilichowski raised the firm’s price target on Sabra Health Care (SBRA) to $22 from $21 and keeps an Overweight rating on the shares. The firm continues…
Sabra Health Care REIT, Inc. to Attend the 2026 NIC Spring Conference
TUSTIN, Calif.--(BUSINESS WIRE)---- $SBRA #SBRA--Sabra Health Care REIT, Inc. (Nasdaq: SBRA) announced today that Rick Matros, the company's Chair and Chief Executive Officer, Darrin Smith, the compan...
Sabra Health Care price target raised to $22 from $21 at Truist
Truist analyst Michael Lewis raised the firm’s price target on Sabra Health Care (SBRA) to $22 from $21 and keeps a Hold rating on the shares. The firm sees good…
Sabra Health Care REIT, Inc. to Participate in Deutsche Bank's 2026 Healthcare REIT Summit
TUSTIN, Calif.--(BUSINESS WIRE)---- $SBRA #DBSummit--Sabra Health Care REIT, Inc. (Nasdaq: SBRA) announced today that Rick Matros, the company's Chair and Chief Executive Officer, Michael Costa, the c...
Sabra Health Care price target raised to $21 from $20 at Scotiabank
Scotiabank analyst Nicholas Yulico raised the firm’s price target on Sabra Health Care (SBRA) to $21 from $20 and keeps a Sector Perform rating on the shares. The firm is…
Sabra Health Care price target raised to $21 from $20 at UBS
UBS analyst Michael Goldsmith raised the firm’s price target on Sabra Health Care (SBRA) to $21 from $20 and keeps a Neutral rating on the shares.
Sabra Health Care price target raised to $24 from $21 at Citi
Citi analyst Nick Joseph raised the firm’s price target on Sabra Health Care (SBRA) to $24 from $21 and keeps a Buy rating on the shares.
Sabra Health Care price target raised to $23 from $22 at BofA
BofA analyst Farrell Granath raised the firm’s price target on Sabra Health Care (SBRA) to $23 from $22 and keeps a Buy rating on the shares. The firm updated estimates…
Sabra Health Care price target raised to $21 from $20 at Cantor Fitzgerald
Cantor Fitzgerald analyst Richard Anderson raised the firm’s price target on Sabra Health Care (SBRA) to $21 from $20 and keeps a Neutral rating on the shares. While the company…
Sabra Health Care REIT, Inc. to Attend Citi's 2026 Global Property CEO Conference
TUSTIN, Calif.--(BUSINESS WIRE)---- $SBRA #CITI--Sabra Health Care REIT, Inc. (Nasdaq: SBRA) announced today that Rick Matros, the company's Chair and Chief Executive Officer; Michael Costa, the compa...